Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
Status:
Unknown status
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
This clinical trial studies magnetic resonance imaging (MRI) using a contrast imaging agent
ferumoxytol (ferumoxytol non-stoichiometric magnetite) in improving viewing tumors in
patients with high-grade brain tumors or cancer that has spread to the brain. Diagnostic
procedures, such as MRI, may help find and diagnose brain tumors and find out how far the
disease has spread. The contrast imaging agent ferumoxytol non-stoichiometric magnetite
consists of small iron particles taken by the blood stream to the brain and to the area of
the tumor. It may help visualize the blood flow going through the tumor better than the
standard substance gadolinium-based contrast agent.